HCMSG - Hepatitis C Mentor & Support Group, Inc.

  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us
  • Home
  • OUR SERVICES
    • Our Services Map
    • THE CIRCLE Registration
    • The Circle Model >
      • How does the Circle Model Work
      • Sites
      • Group and Facilitator Guide
      • Circle Model Data Form
    • TRAINING >
      • HepCTraining
  • RESOURCES
  • Blog
  • About Us
    • Our Mission
    • Board of Directors
    • Medical Advisors
    • Support Us
    • Contact Us

Outcomes of Rapid Treatment With Sofosbuvir-Velpatasvir in Patients With Hepatitis C Virus who use Injectable Drugs

10/6/2021

0 Comments

 
Madison Heck, MPH, CHES
​
The following article is a part of conference coverage from the IDWeek 2021, being held virtually from September 29 to October 3, 2021. The team at Infectious Disease Advisor will be reporting on the latest news and research conducted by leading experts in the field. Check back for more from the IDWeek 2021.
Among patients with hepatitis C virus (HCV) infection with a history of injectable drug use, those who underwent rapid treatment with a 7-day course of sofosbuvir-velpatasvir achieved significantly increased cure rates compared with those treated with usual care, according to research presented at IDWeek, held virtually from September 29 to October 3, 2021.


 Researchers conducted a study on patients aged 18 to 29 years with HCV who were treatment naïve and had used injectable drugs within the past 30 days. Patients were randomly assigned in a 1:1 fashion to receive either rapid treatment with sofosbuvir-velpatasvir or usual care. In addition to a 7-day course of sofosbuvir-velpatasvir, patients in the rapid treatment group received a same-day medical evaluation, confirmatory and baseline laboratory testing. Patients in the usual care group received same-day HCV confirmation and facilitated referral to a local healthcare provider. The primary endpoint was sustained virologic response at 12 months.

​TO CONTINUE: https://www.infectiousdiseaseadvisor.com/home/meetings/id-week-2021/sofosbuvir-velpatasvir-treatment-in-patients-with-hepatitis-c-who-inject-drugs/
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021

    Categories

    All

    RSS Feed

Privacy Policy
Disclaimer:  Information given by Hepatitis C Mentor and Support Group is not a substitute for advice given by your physician or health care provider.  We do not endorse any doctor, hospital, medical group, or treatment.